Categories Earnings, Retail

Barnes & Noble trims loss in Q2

Barnes & Noble (BKS) trimmed down its loss in the second quarter of 2019 with a year-over-year drop in sales. The bookseller’s loss stood at $27.4 million, or $0.38 per share compared to a loss of $30.1 million, or $0.41 per share in the prior year quarter. Revenue declined 2.5% to $771 million, while comp store sales decreased 1.4%.

Barnes & Noble second quarter 2019 Earnings Infographic

Once the book-selling juggernaut Barnes & Noble announced last month that the board is exploring options after it has got inquiries from various firms to acquire the retailer. The potential parties that showed interest in taking over the company included its current Chairman Leonard Riggio.

“While we cannot predict the outcome of the holiday, we are putting our full effort behind our holiday plans, including launching a new ad campaign. We expect this to lead to continued sales improvement during the holiday period,” said Leonard Riggio.

For fiscal 2019, Barnes & Noble continues to expect EBITDA to be in a range of $175 million to $200 million, excluding unusual or non-recurring items.

Earlier in July, the company axed its CEO Demos Parneros, who didn’t even complete one year as the bookseller’s CEO. In August, Parneros filed a case against the company, mainly alleging its Chairman Riggio. Then, the company came out with the reasons for terminating Parneros and accused him of sexual harassment and violating other company policies.

Barnes & Noble surges above 20%; board to explore sale

The New York-based company’s shares closed down 2.31% at $6.76 on Monday and were down 2.5% when the market opened today. The stock dropped 1% in the year-to-date period, while declining 9% in the past 52-weeks.

 

Get access to timely and accurate verbatim transcripts that are published within hours of the event

Most Popular

IPO Alert: What to look for when Boundless Bio goes public

Boundless Bio is preparing to debut on the Nasdaq stock market this week, and become the latest addition to the list of biotech firms that have launched IPOs this year.

Nike (NKE) bets on innovation and partnerships to return to high growth

Sneaker giant Nike, Inc. (NYSE: NKE) has been going through a rough patch for some time, with sales coming under pressure from weak demand and rising competition. Post-pandemic, the company

Walgreens Boots Alliance set to report earnings next week. Here’s what to expect

Walgreens Boots Alliance, Inc. (NASDAQ: WBA), the drug store chain that is expanding into a diversified healthcare provider, is on a restructuring drive aimed at better aligning the business with

Tags

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top